The acquisition closed on July 16, 2026 (SEC 8-K 2.01). Its last closing price was on July 14, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from July 1, 2026. Source: SEC 8-K 2.01
CATALYST PHARMACEUTICALS, INC. CPRX
NasdaqMid CapHealthcare
Final 13F Pro quality score
Final rank #91 of 2,856 · as of July 1, 2026TOP 5%
AI-extracted from the 10-Q filed 2026-05-11 — Q1 FY2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Total revenue rose 5.6% to $149.4M as FIRDAPSE (+18.1%) and AGAMREE (+66.6%) growth offset a 61.3% FYCOMPA collapse, while Catalyst agreed to be acquired by Angelini Pharma for $31.50 per share.
Biggest Revenue Drivers
Product revenue, net$149.3M+5.6% YoY
Primarily driven by increases in sales volumes for both FIRDAPSE and AGAMREE
License and other revenue$47 thousand+123.8% YoY
Consisted of royalties
Biggest Revenue Drivers
Total revenue: $149.4M+5.6% YoY
Product revenue, net$149.3M+5.6% YoY
Primarily driven by increases in sales volumes for both FIRDAPSE and AGAMREE
Within Product revenue, net
FIRDAPSE®$98.9M+18.1% YoY
Increase in sales volumes
AGAMREE®$36.7M+66.6% YoY
Increase in sales volumes
FYCOMPA®$13.8M-61.3% YoY
Generic entry following loss of exclusivity in 2025
License and other revenue$47 thousand+123.8% YoY
Consisted of royalties
Largest Expense Items
Selling, general and administrative$49.3M+5.1% YoY
Increase in general and administrative from consulting fees related to multiple business initiatives, including business development
Cost of sales$14.5M-19% YoY
Primarily a decrease in royalty obligations related to FIRDAPSE
Amortization of intangible assets$9.7M
FYCOMPA, RUZURGI and AGAMREE rights amortized straight-line over 5, 14.5 and 10.5 years
Research and development$2.7M-31.5% YoY
Research and clinical trial expense fell $0.9M, or 45.4%
Margins: Operating income rose to $73.2M from $63.4M as cost of sales fell to $14.5M on lower FIRDAPSE royalties; the overall upstream FIRDAPSE royalty rate dropped to 6% from a prior maximum of 18.5%.
Watch Items from the Filing
Pending merger with Angelini Pharma at $31.50 per share cash; a termination fee of approximately $155.5 million applies under specified circumstances.
Customer A represented 90.1% of total net product revenue, up from 74.0% a year earlier.
FYCOMPA revenue fell to $13.8M from $35.6M; the company expects further declines and ceased all marketing for the product at the end of 2025.
Hetero FIRDAPSE patent litigation settled with market entry no earlier than January 2035, but Catalyst owes an $11.0 million litigation avoidance fee in Q2 2026.
Effective tax rate rose to 24.3% from 20.4%; company also relies on Santhera as sole AGAMREE supplier while transitioning manufacturing by end of 2026.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Andrews William T.Chief Medical OfficerDisposition to issuer · Jul 15, 2026
Daly Richard JPresident and CEODisposition to issuer · Jul 15, 2026
Sundaram PreethiChief Strategy OfficerDisposition to issuer · Jul 15, 2026
Del Carmen JeffreyChief Commercial OfficerDisposition to issuer · Jul 15, 2026
Denkhaus Donald ADirectorDisposition to issuer · Jul 15, 2026
Mcenany Patrick JDirectorDisposition to issuer · Jul 15, 2026
Russo GreggChief HR OfficerDisposition to issuer · Jul 15, 2026
Thompson TamarDirectorDisposition to issuer · Jul 15, 2026
About CATALYST PHARMACEUTICALS, INC. (CPRX): stock profile, AI score and financials
Acquired by Angelini Pharma S.p.A.: CATALYST PHARMACEUTICALS, INC. (CPRX) no longer trades and has left 13F Pro's AI-ranked universe. The acquisition closed on July 16, 2026 (SEC 8-K 2.01). Its last closing price was on July 14, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from July 1, 2026. CATALYST PHARMACEUTICALS, INC. (CPRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro tracks CPRX using direct SEC EDGAR data and AI-powered research tools. Based on the latest XBRL financial filings (Q1 2026), CATALYST PHARMACEUTICALS, INC. reports quarterly revenue of $149.4M, net income of $63.7M, an operating margin of 49.0%. Top institutional holders of CPRX by reported 13-F value include BlackRock, STATE STREET, AMERICAN CENTURY COMPANIES, based on the most recent SEC filings. CPRX trades on the Nasdaq exchange and files with the SEC under CIK 1369568. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CPRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CATALYST PHARMACEUTICALS, INC. directly from SEC EDGAR.